{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:28:46Z","timestamp":1790832526719,"version":"4.1.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20299"],"award-info":[{"award-number":["20299"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["17273"],"award-info":[{"award-number":["17273"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02722","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:01:48Z","timestamp":1543363308000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":163,"title":["CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma"],"prefix":"10.3389","volume":"9","author":[{"given":"Fabio","family":"Morandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto L.","family":"Horenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Pistoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Malavasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2141.2004.05207.x","article-title":"A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK","volume":"127","author":"Phekoo","year":"2004","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.4049\/jimmunol.145.8.2390","article-title":"Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation","volume":"145","author":"Funaro","year":"1990","journal-title":"J Immunol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1182\/blood-2007-07-101600","article-title":"Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse","volume":"111","author":"Munoz","year":"2008","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1126\/science.8235624","article-title":"Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38","volume":"262","author":"Howard","year":"1993","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood-2013-02-483511","article-title":"Intracellular NAD(+) depletion enhances bortezomib-induced anti-myeloma activity","volume":"122","author":"Cagnetta","year":"2013","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fimmu.2017.00305","article-title":"Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche","volume":"8","author":"Chillemi","year":"2017","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1155\/2015\/341430","article-title":"Mechanisms of drug resistance in relapse and refractory multiple myeloma","volume":"2015","author":"Yang","year":"2015","journal-title":"BioMed Res Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"56598","DOI":"10.18632\/oncotarget.17896","article-title":"Expression of CD38 in myeloma bone niche: a rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J."},{"key":"B20","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1182\/blood.V126.23.4244.4244","article-title":"Treatment of ex vivo expanded NK cells with Daratumumab F(ab')2 fragments protects adoptively transferred NK cells from Daratumumab-mediated killing and augments Daratumumab-induced Antibody Dependent Cellular Toxicity (ADCC) of myeloma","volume":"126","author":"Cherkasova","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of Daratumumab","volume":"129","author":"Garcia-Guerrero","year":"2017","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood.V124.21.2096.2096","article-title":"Modulation of CD38 expression levels on multiple myeloma tumor cells by all-trans retinoic acid improves the efficacy of the anti-CD38 monoclonal antibody Daratumumab","volume":"124","author":"Nijhof","year":"2014","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood.V120.21.2974.2974","article-title":"Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking","volume":"120","author":"Jansen","year":"2012","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fc\u03b3 receptor\u2013mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"De Weers","year":"2011","journal-title":"J Immunol."},{"key":"B27","doi-asserted-by":"crossref","first-page":"SCI","DOI":"10.1182\/blood.V128.22.SCI-36.SCI-36","article-title":"CD38 and Antibody therapy: what can basic science add?","volume":"128","author":"Malavasi","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1458809","DOI":"10.1080\/2162402X.2018.1458809","article-title":"Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+","volume":"7","author":"Morandi","year":"2018","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab","volume":"96","author":"Van Der Veer","year":"2011","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"Van De Donk","year":"2018","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V77.5.1071.1071","article-title":"Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody","volume":"77","author":"Stevenson","year":"1991","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4049\/jimmunol.155.2.925","article-title":"Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma","volume":"155","author":"Ellis","year":"1995","journal-title":"J Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"27055","DOI":"10.1038\/srep27055","article-title":"Immuno-targeting the multifunctional CD38 using nanobody","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1038\/s41598-017-14112-6","article-title":"Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo","volume":"7","author":"Fumey","year":"2017","journal-title":"Sci Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/HAB-160294","article-title":"A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen","volume":"24","author":"Barabas","year":"2016","journal-title":"Hum Antibodies"},{"key":"B40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3233\/HAB-160295","article-title":"Suppression of tumor growth by a heterologous antibody directed against multiple myeloma dominant CD38 antigen in SCID mice injected with multiple myeloma cells","volume":"24","author":"Barabas","year":"2016","journal-title":"Hum Antibodies"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1158\/0008-5472.CAN-13-1589","article-title":"A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies","volume":"74","author":"Green","year":"2014","journal-title":"Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/blood-2017-09-807610","article-title":"CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.18632\/oncotarget.2986","article-title":"alpha-Radioimmunotherapy with (2)(1)(3)Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma","volume":"6","author":"Teiluf","year":"2015","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"B49","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/leu.2011.205","article-title":"T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells","volume":"26","author":"Mihara","year":"2012","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1182\/blood.V124.21.4759.4759","article-title":"CD38 chimeric antigen receptor engineered T cells as therapeutic tools for multiple myeloma","volume":"124","author":"Drent","year":"2014","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0197349","DOI":"10.1371\/journal.pone.0197349","article-title":"Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design","volume":"13","author":"Drent","year":"2018","journal-title":"PLoS ONE"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/cti.2016.73","article-title":"All-trans retinoic acid enhances the cytotoxic effect of T cells with anti-CD38 chimeric receptor in acute myeloid leukemia","volume":"120","author":"Mihara","year":"2012","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.2017.35.15_suppl.103","article-title":"The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL)","volume":"35","author":"Maude","year":"2017","journal-title":"J Clin Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.clml.2017.03.029","article-title":"Depth of response and MRD with Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX","volume":"17","author":"San-Miguel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clml.2017.03.153","article-title":"Depth of response and MRD with Daratumumab plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR","volume":"17","author":"Spencer","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T12:21:46Z","timestamp":1694089306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":59,"alternative-id":["10.3389\/fimmu.2018.02722"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02722","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"article-number":"2722"}}